ENTITY
WuXi XDC Cayman

WuXi XDC Cayman (2268 HK)

50
Analysis
Health CareChina
WuXi XDC Cayman Inc. operates as a leading contract testing, development and manufacturing organization focused on the global antibody drug conjugates and broader bioconjugate market. The Company provides bioconjugation discovery, analytical development, intermediate and conjugation manufacturing, and other services. WuXi XDC Cayman provides its services worldwide.
more
Refresh
bullishWuXi XDC Cayman
16 Nov 2023 16:00

Wuxi XDC: Thoughts on First Day Trading

​Wuxi XDC priced its IPO at HK$20.60 per share, at the upper end of the IPO price range. The company raised HK$3.5bn and the offering was...

Share
bullishWuXi XDC Cayman
16 Nov 2023 15:32

WuXi XDC IPO: Trading Debut

The market sentiment on the sector has modestly weakened. However, the IPO price is attractive, with our DCF valuation of HK$22.89 per share, 11.1%...

Logo
390 Views
Share
bullishWuXi XDC Cayman
16 Nov 2023 08:09

WuXi XDC Cayman IPO Trading - Strong Subscription Rates Heading into Listing

WuXi XDC Cayman (1877628D HK) raised US$470m in its Hong Kong IPO. In our previous notes, we looked at the company’s past performance and...

Logo
428 Views
Share
bullishWuXi XDC Cayman
14 Nov 2023 06:20

WuXi XDC (2268 HK): Index Inclusion Possibility & Timelines

WuXi XDC is looking to raise up to US$521m in its IPO. A large chunk is being taken by cornerstone investors. HSCI and Stock Connect inclusion...

Logo
481 Views
Share
bullishWuXi XDC Cayman
09 Nov 2023 16:52

Wuxi XDC IPO: Forecasts and Valuation

​Wuxi plans to raise around US$479m through its HKEx IPO. We have valued the company's IPO using a DCF which offers more than 10% upside to the...

Share
x